
- Research indicates that a new once-daily tablet called AR1001, which works in a similar way to erectile dysfunction medication Viagra, could slow cognitive decline in patients with early-stage Alzheimer's disease.
- Results from a year-long trial conducted by South Korean firm AriBio showed that AR1001 reduced clinical deterioration in memory and thinking by 31 per cent in a cohort of 604 patients who were taking no other Alzheimer's therapies.
- As a phosphodiesterase-5 inhibitor, the drug operates via a novel mechanism by relaxing blood vessels to increase blood flow to the brain, targeting the root causes of early Alzheimer's rather than merely treating its symptoms.
- The trial revealed that AR1001 failed to deliver statistically significant benefits for patients who were concurrently taking other Alzheimer's medications, indicating that further research is required to understand these interactions.
- Representatives from the Alzheimer's Society in the UK welcomed the promising topline findings as an exciting sign for future dementia care, whilst cautioning that the drug must undergo full regulatory assessment and warning the public not to take Viagra as an Alzheimer's treatment.
IN FULL

